Exploring how genetic factors influence opioid effects in a model organism.
Genetic Characterization and Exploration of Mu-Opioid Receptor Signaling in C. elegans
This study is looking at how certain genes affect how our bodies respond to pain relief from opioids, using tiny worms that have been modified to mimic human reactions, to help find safer ways to use these medications for people who need them.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11066344 on NIH RePORTER |
What this research studies
This research investigates the mu-opioid receptor (MOR), which is crucial for pain relief but can lead to tolerance and abuse. Using a unique model organism, C. elegans, that has been genetically modified to express human MOR, the study aims to understand how different genetic components affect the behavior and response to opioid drugs. By employing techniques like CRISPR, researchers will manipulate specific genes to see how they influence opioid-induced behaviors, providing insights into safer opioid use. This work is particularly relevant for understanding the genetic and neuropharmacological changes associated with opioid use.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are experiencing pain and may require opioid treatment, particularly those concerned about the risks of tolerance and addiction.
Not a fit: Patients who do not use opioids or have no interest in opioid treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of safer opioid medications with reduced side effects and lower potential for abuse.
How similar studies have performed: Other research has shown promise in using genetic models to study opioid signaling, indicating that this approach could yield valuable insights.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Coleman, Dez — University of Washington
- Study coordinator: Coleman, Dez
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.